Glukem Pharmaceuticals Private Limited, a active private limited company, was established on 10 February 2009 in Hyderabad, Telangana, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24233TG2009PTC062750. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹1.00 Cr.
It upholds a compliant status. Its leadership includes Rakesh Chinnala (Director), Varun Vihar Madupaduga (Director), Rami Reddy Kolli (Director). Past directors included Nagi Reddy Seelam, Rakesh Chinnala, Kolli Surendra Reddy. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 10-5-447, Ground Floor, Jyothi Vihar Tukaram Gate North Lalaguda,Secunderabad, Hyderabad, Telangana, 500017.
U24233TG2009PTC062750
062750
10 February 2009
₹1.00 Cr
₹1.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Glukem Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rakesh Chinnala | Director | 01 Aug 2015 | Current |
| Varun Vihar Madupaduga | Director | 05 Feb 2015 | Current |
| Rami Reddy Kolli | Director | 01 Aug 2015 | Current |
| Hazra Susanta Kumar | Director | 01 Aug 2015 | Current |
| Ramanaiah Madupaduga | Managing Director | 05 Feb 2015 | Current |
| Omkar Reddy Bommu | Director | 01 Aug 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 07 Feb 2015 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
| Pramod Abcsdd | Director | 08 Dec 2009 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
| Pramod Abcsdd | Director | 05 Sep 2013 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Glukem Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 7459% decrease in profit. The company's net worth dipped by a decrease of 4%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Glukem Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Glukem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Glukem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glukem Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Glukem Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Glukem Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
Rakesh Chinnala was appointed as a Director was appointed as a Director on 01 Aug 2015 & has been associated with this company since 10 years 4 months . was recorded as a recent event.
The activity Rami Reddy Kolli was appointed as a Director was appointed as a Director on 01 Aug 2015 & has been associated with this company since 10 years 4 months . was completed.
The activity Hazra Susanta Kumar was appointed as a Director was appointed as a Director on 01 Aug 2015 & has been associated with this company since 10 years 4 months . was completed.
The activity Omkar Reddy Bommu was appointed as a Director was appointed as a Director on 01 Aug 2015 & has been associated with this company since 10 years 4 months . was completed.
The CIN of Glukem Pharmaceuticals Private Limited is U24233TG2009PTC062750.
Glukem Pharmaceuticals Private Limited is headquartered at 10-5-447, Ground Floor, Jyothi Vihar Tukaram Gate North Lalaguda,Secunderabad, Hyderabad, Telangana, 500017.
Glukem Pharmaceuticals Private Limited was incorporated on 10 February 2009.
The current directors of Glukem Pharmaceuticals Private Limited are
The primary industry of Glukem Pharmaceuticals Private Limited is Manufacturing.
Glukem Pharmaceuticals Private Limited is unlisted.
The authorized capital of Glukem Pharmaceuticals Private Limited is ₹1.00 Cr, and the paid-up capital is ₹1.00 Cr.
The compliance status of Glukem Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX